Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text

Medicine, Ophthalmology, Surgery +12

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels et al. · New England Journal of Medicine · 2006 · 3.5K citations

Medicine, Ophthalmology, Pharmacotherapy +13

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry et al. · New England Journal of Medicine · 2003 · 2.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pegaptanib for Neovascular Age-Related Macular Degeneration

Evangelos S. Gragoudas, Anthony P. Adamis, Emmett T. Cunningham et al. · New England Journal of Medicine · 2004 · 2.3K citations · Full text

Medicine, Ophthalmology, Pharmacology +11

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

David M. Brown, Mark Michels, Peter K. Kaiser et al. · Ophthalmology · 2008 · 1.3K citations

Medicine, Ophthalmology, Surgery +15